Evidence map›Paper›PMID 39037602›Full record

ArticleDiabetologia2024

Estimating risk of consequences following hypoglycaemia exposure using the Hypo-RESOLVE cohort: a secondary analysis of pooled data from insulin clinical trials.

Joseph Mellor, Dmitry Kuznetsov, Simon Heller, Mari-Anne Gall, Myriam Rosilio, Stephanie A Amiel, Mark Ibberson, Stuart McGurnaghan, Luke Blackbourn, William Berthon and 8 more

Abstract read
In one paragraph

Article in Diabetologia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Observational
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Joseph MellorUsher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK. joe.mellor@ed.ac.uk.ORCID http://orcid.org/0000-0003-1452-887X
Dmitry KuznetsovSwiss Institute of Bioinformatics, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-9972-947X
Simon HellerDivision of Clinical Medicine, University of Sheffield, Sheffield, UK.ORCID http://orcid.org/0000-0002-2425-9565
Mari-Anne GallMedical & Science, Insulin, Clinical Drug Development, Novo Nordisk A/S, Soeberg, Denmark.ORCID http://orcid.org/0000-0001-7149-0092
Myriam RosilioDiabetes Medical Unit, Eli Lilly and Company, Neuilly-sur-Seine, France.ORCID http://orcid.org/0000-0003-0296-9061
Stephanie A AmielDepartment of Diabetes, School of Cardiovascular and Metabolic Medicine and Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.ORCID http://orcid.org/0000-0003-2686-5531
Mark IbbersonSwiss Institute of Bioinformatics, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-3152-5670
Stuart McGurnaghanInstitute of Genetics and Cancer, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.ORCID http://orcid.org/0000-0002-3292-4633
Luke BlackbournInstitute of Genetics and Cancer, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.ORCID http://orcid.org/0000-0003-4234-8040
William BerthonUsher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.ORCID http://orcid.org/0000-0003-1776-4798
Adel SalemRW Data Assets, AI & Analytics(AIA), Novo Nordisk A/S, Soeberg, Denmark.ORCID http://orcid.org/0009-0004-7056-4466
Yongming QuEli Lilly and Company, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0003-3643-8066
Rory J McCrimmonSystems Medicine, School of Medicine, University of Dundee, Dundee, UK.ORCID http://orcid.org/0000-0002-3957-1981
Bastiaan E de GalanDivision of Endocrinology and Metabolic Disease, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands.ORCID http://orcid.org/0000-0002-1255-7741
Ulrik Pedersen-BjergaardInstitute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0003-0588-4880
Joanna LeavissSchool of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK.ORCID http://orcid.org/0000-0002-5632-6021
Paul M McKeigueUsher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.ORCID http://orcid.org/0000-0002-5217-1034
Helen M ColhounInstitute of Genetics and Cancer, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.ORCID http://orcid.org/0000-0002-8345-3288

Funding

Innovative Medicines Initiative 777460
6 · The paper itself

Abstract

aims/hypothesisWhether hypoglycaemia increases the risk of other adverse outcomes in diabetes remains controversial, especially for hypoglycaemia episodes not requiring assistance from another person. An objective of the Hypoglycaemia REdefining SOLutions for better liVEs (Hypo-RESOLVE) project was to create and use a dataset of pooled clinical trials in people with type 1 or type 2 diabetes to examine the association of exposure to all hypoglycaemia episodes across the range of severity with incident event outcomes: death, CVD, neuropathy, kidney disease, retinal disorders and depression. We also examined the change in continuous outcomes that occurred following a hypoglycaemia episode: change in eGFR, HbA

methodsData from 84 trials with 39,373 participants were pooled. For event outcomes, time-updated Cox regression models adjusted for age, sex, diabetes duration and HbA

resultsThe maximally adjusted association analysis for type 1 diabetes found that cumulative exposure to hypoglycaemia episodes of any level was associated with higher risks of neuropathy, kidney disease, retinal disorders and depression, with risk ratios ranging from 1.55 (p=0.002) to 2.81 (p=0.002). Associations of a similar direction were found when level 1 episodes were examined separately but were significant for depression only. For type 2 diabetes cumulative exposure to hypoglycaemia episodes of any level was associated with higher risks of death, acute CVD, kidney disease, retinal disorders and depression, with risk ratios ranging from 2.35 (p<0.0001) to 3.00 (p<0.0001). These associations remained significant when level 1 episodes were examined separately. There was evidence of an association between hypoglycaemia episodes of any kind in the previous 10 days and death, acute CVD and retinal disorders in both type 1 and type 2 diabetes, with rate ratios ranging from 1.32 (p=0.017) to 2.68 (p<0.0001). These associations varied in magnitude and significance when examined separately by hypoglycaemia level. Within the range of hypoglycaemia defined by levels 1, 2 and 3, we could not find any evidence of a threshold at which risk of these consequences suddenly became pronounced. CONCLUSIONS/

interpretationThese data are consistent with hypoglycaemia being associated with an increased risk of adverse events across several body systems in diabetes. These associations are not confined to severe hypoglycaemia requiring assistance.

Indexed as

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2HypoglycemiaHypoglycemic AgentsInsulinAdultAgedBlood GlucoseCardiovascular DiseasesCohort StudiesFemaleGlycated HemoglobinHumansMaleMiddle AgedBlood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulinConsequencesCox regressionHypoglycaemiaHypo-RESOLVE

Identifiers

PMID39037602
PMCPMC11447089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.